Novo Nordisk Eyes U.S. Expansion to Dodge Tariff Hit on Wegovy

By James, Admin
March 21, 2025 – 10:10 AM PDT, Raleigh, NC

Novo Nordisk A/S broke ground today on a $4.1 billion expansion in North Carolina, a strategic leap to shield its blockbuster drug Wegovy from looming U.S. tariffs. CEO Lars Fruergaard Jørgensen, speaking at the Raleigh site, called it “a hedge against trade uncertainty,” as Washington mulls a 25% levy on European imports. The move aims to localize production of Wegovy and Ozempic, fueling Novo’s U.S. dominance in obesity and diabetes care.

The facility, set to open in 2027, will span 1 million square feet and pump out 1.5 million doses monthly—doubling Novo’s U.S. capacity. It’s a direct response to tariff talks reignited by Trump’s DOGE push, which could slap $500 million in annual costs on Novo’s imports from Denmark. Jørgensen said the shift also tackles supply woes—Wegovy’s been on backorder since 2023, with demand outstripping output fivefold. Shares rose 2% on the news.

North Carolina’s no random pick. Its biotech hub, low taxes, and 1,000 promised jobs won Novo over, with Governor Roy Cooper hailing it as “a win for the Triangle.” The plant will use cutting-edge automation to churn out semaglutide, Wegovy’s active ingredient, while a $200 million R&D wing tests next-gen obesity drugs. Novo’s also locked in local suppliers for packaging, dodging overseas bottlenecks.

The tariff threat’s real—U.S. imports of EU pharma hit $80 billion last year, and Novo’s $20 billion in stateside sales make it a prime target. Analysts say local production could save $300 million yearly if duties kick in, though construction costs might offset that short-term. The move’s a stark pivot from Novo’s Europe-centric model, where 80% of its manufacturing sits—Denmark’s losing some shine as a result.

Challenges pile up, though. Last week’s CagriSema trial flopped—weight loss lagged expectations—denting Novo’s pipeline and pressuring Wegovy to carry the load. The U.S. expansion’s a lifeline, but it’s not cheap; Novo’s tapping $2 billion in debt to fund it, a gamble if demand softens. Competitors like Eli Lilly, with its rival Zepbound, are watching—Lilly’s U.S.-based production gives it a tariff edge already.

Novo’s playing long ball. The Raleigh plant will hit full stride by 2029, aligning with forecasts of a $100 billion obesity market. Jørgensen teased “more U.S. investments” if tariffs stick, hinting at Ohio or Texas next. For now, it’s about securing Wegovy’s 60% market share—10 million Americans use it, and Novo wants that locked in before trade wars bite.

The stakes extend beyond Novo. A tariff dodge could set a precedent for pharma giants like Pfizer, reshaping global supply chains. Raleigh’s buzzing with optimism—local colleges are already pitching biotech grads—but Novo’s got to nail execution. Today’s groundbreaking’s a start; the real test is keeping the drug flowing and the costs in check.
​